Last Update Time:
21-Mar-2025 16:00:00
ISIN:
INE031B01049
Sector:
Healthcare
Symbol:
AJANTPHARM
Ajanta Pharma Limited
₹2,732.05
₹105.70
(4.02%)
▲
Prev. Close
₹2,626.35
Open
₹2,654.25
Close
₹2,714.10
Range
₹2,595.45 - ₹2,868.65
High
₹2,881.50
Low
₹2,630.05
Ind. Close
₹0.00
VWAP
₹2,738.92
The current stock price of Ajanta Pharma Limited is ₹2,732.05, with a target price range between ₹2,595.45 and ₹2,868.65. The stock has experienced a price change of ₹105.70 (4.02%), reflecting recent market volatility.
Today's opening price was ₹2,654.25, while the previous close stood at ₹2,626.35.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Ajanta Pharma Limited Price Chart
Ajanta Pharma Limited Pre Open Market Overview: 21-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 2654.25
- Previous Close Price: 2626.35
- Change: 27.90%
- Total Traded Volume: 176
- Total Buy Quantity: 923
- Total Sell Quantity: 2,404
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 2,621.50 | 20.00 | 0.00 |
| 2,623.05 | 3.00 | 0.00 |
| 2,623.15 | 5.00 | 0.00 |
| 2,630.00 | 1.00 | 0.00 |
| 2,632.00 | 11.00 | 0.00 |
| 2,654.25 | 0.00 | 157.00 |
| 2,656.35 | 0.00 | 1,000.00 |
| 2,665.00 | 0.00 | 1.00 |
| 2,669.00 | 0.00 | 20.00 |
| 2,670.00 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 923
Total Sell Quantity: 2404
Shareholding Patterns of Ajanta Pharma Limited
Key Trade Statistics of Ajanta Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 10.64 |
| Traded Value (₹ Cr.) | 291.49 |
| Total Market Cap (₹ Cr.) | 34,126.61 |
| Free Float Market Cap (₹ Cr.) | 11,471.42 |
| Impact cost | 0.06 |
| Quantity Traded | 1,064,254.00 |
| Deliverable Quantity | 420,559.00 |
| % of Quantity to Traded | 39.52 |
| Security VaR | 14.12 |
| Index VaR | N/A |
| VaR Margin | 14.12 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 17.62 |
| Face Value | 2 |
Key Price Statistics of Ajanta Pharma Limited
The 52-week high for Ajanta Pharma Limited was ₹3,485.00, recorded on 12-Sep-2024. On the other hand, the 52-week low stands at ₹2,051.60, with the lowest value recorded on 16-Apr-2024.
The upper band for trading is ₹3,151.60, and the lower band is ₹2,101.10. The price band is 20%.
The stock's daily volatility stands at 2.20, while the annualized volatility is 42.03. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (12-Sep-2024) | 3,485.00 |
| 52 Week Low (16-Apr-2024) | 2,051.60 |
| Upper Band | 3,151.60 |
| Lower Band | 2,101.10 |
| Price Band (%) | 20 |
| Daily Volatility | 2.20 |
| Annualised Volatility | 42.03 |
| Tick Size | 0.05 |
Key Securities Statistics of Ajanta Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 29-May-2000 |
| Adjusted P/E | 36.54 |
| Symbol P/E | 36.54 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Ajanta Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Ajanta Pharma Limited
| Subject | Date |
|---|---|
| Capacity addition | 20-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 20-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 07-Feb-2025 |
| Integrated Filing- Financial | 05-Feb-2025 |
| Updates | 05-Feb-2025 |
| Rumour Verification - Regulation 30(11) | 04-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 03-Feb-2025 |
| Copy of Newspaper Publication | 31-Jan-2025 |
Corporate Actions of Ajanta Pharma Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Interim Dividend - Rs 28 Per Share | 06-Nov-2024 |
| 2 | Buy Back | 30-May-2024 |
| 2 | Interim Dividend - Rs 26 Per Share | 08-Feb-2024 |
| 2 | Interim Dividend - Rs 10 Per Share/Special Dividend - Rs 15 Per Share | 04-Aug-2023 |
| 2 | Buy Back | 24-Mar-2023 |
| 2 | Interim Dividend - Rs 7 Per Share | 11-Nov-2022 |
| 2 | Bonus- 1:2 | 22-Jun-2022 |
| 2 | Buyback | 13-Jan-2022 |
| 2 | Interim Dividend - Rs 9.50 Per Share | 09-Nov-2021 |
| 2 | Interim Dividend - Rs 9.50 Per Share | 12-Nov-2020 |
| 2 | Buyback | 12-Nov-2020 |
| 2 | Annual General Meeting | 21-Jul-2020 |
| 2 | Interim Dividend - Rs 13 Per Share | 15-Nov-2019 |
| 2 | Annual General Meeting | 09-Jul-2019 |
| 2 | Buy Back | 11-Feb-2019 |
| 2 | Interim Dividend - Rs 9 Per Sh | 09-Nov-2018 |
| 2 | Annual General Meeting | 26-Jun-2018 |
| 2 | Annual General Meeting | 23-Jun-2017 |
| 2 | Interim Dividend Rs 7/- Per Share (Purpose Revised) | 23-Mar-2017 |
| 2 | Interim Dividend Rs 6/- Per Share | 07-Nov-2016 |
Board Meetings of Ajanta Pharma Limited
Financial Results of Ajanta Pharma Limited
Company Directory of Ajanta Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.ajantapharma.com | Registered Office | Ajanta House 98, Govt. Industrial Area Charkop Kandivali (w) | MUMBAI |
| www.ajantapharma.com | Transfer Agent | Link Intime (India) Private Limited C-101, 247 PARK L B S MARG Vikhroli West | MUMBAI |
Insider Trading of Ajanta Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | VANDANA SHAILESH SINGH | 1491902 | Sell |
| 7(2) | J K TRIPATHI | 158100 | Sell |
| 7(2) | J K TRIPATHI | 295000 | Sell |
| 7(2) | J K TRIPATHI | 289500 | Sell |
| 7(2) | J K TRIPATHI | 300000 | Sell |
| 7(2) | J K TRIPATHI | 149940 | Sell |
| 7(2) | ARVIND K AGRAWAL | 2000 | Buy |
| 7(2) | SEEMA AGRAWAL | 16436150 | Sell |
| 7(2) | ARVIND K AGRAWAL | 19761720 | Sell |
| 7(2) | J K TRIPATHI | 561706 | Sell |
| 7(2) | J K TRIPATHI | 320000 | Sell |
| 7(2) | J K TRIPATHI | 299103 | Sell |
| 7(2) | J K TRIPATHI | 1000 | Buy |
| 7(2) | AAYUSH M AGRAWAL, TRUSTEE AAYUSH AGRAWAL TRUST | 53993 | Pledge |
| 7(2) | AAYUSH M AGRAWAL, TRUSTEE AAYUSH AGRAWAL TRUST | 539883006 | Pledge |
| 7(2) | AAYUSH M AGRAWAL, TRUSTEE AAYUSH AGRAWAL TRUST | 26449200 | Pledge |
| 7(2) | JAGDISH DWARKADAS JOSHI | 5904920 | Sell |
| 7(2) | Ravi Agrawal, Trustee Ravi Agrawal Trust | 1042200000 | Pledge |
| 7(2) | SATISH AGRAWAL | 1994400 | Sell |
| 7(2) | YOGESH M AGRAWAL, TRUSTEE YOGESH AGRAWAL TRUST | 212785860 | Sell |
Annual Reports of Ajanta Pharma Limited
Investor Complaints of Ajanta Pharma Limited
Event Calendar of Ajanta Pharma Limited
| Purpose | Details |
|---|---|
| Results/Dividend | To consider and approve, inter alia, the audited Financial Results for the year ended March 31, 2011 and recommending dividend, if any, on equity shares of the Company for the Financial Year 2010-11. |
| Results/Dividend/Stock-split | To consider and approve, inter alia: (1) The audited Financial Results for the year ended March 31, 2012; (2) Recommending dividend, if any, on equity shares of the Company for the Financial year 2011-12 and (3) Sub-division of shares. |
| Results/Dividend | To consider and approve, inter alia : (1) The audited Financial Results for the year ended March 31, 2013 and (2) Recommending dividend, if any, on equity shares of the Company for the Financial year 2012-13. |
| Result/Bonus | (1) To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2013. (2) To consider Bonus issue of shares. |
| Results | To consider and approve, inter alia, the Unaudited Financial Results for the second quarter and half year ended September 30, 2013. |
| Results | To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2013. |
| Results/Dividend | To consider and approve, inter alia : (1) The audited Financial Results for the year ended March 31, 2014 and (2) Recommend dividend, if any, on equity shares of the Company for the Financial year 2013-14. |
| Appointment of Director | for considering appointment of two Additional Directors of the Company. |
| Results | To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2014. |
| Results | To consider and approve, inter alia, the Unaudited Financial Results for the second quarter and half year ended 30th September, 2014. |
| Results | To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2014. |
| Results/Dividend | to inter alia: 1. Consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2015; 2. Consider and approve Financial Statements for the year ended March 31, 2015 3. Recommend dividend, if any, on equity shares of the Company for the financial year 2014-15. |
| Results | to consider and approve, inter alia Unaudited Financial Results for the first quarter ended June 30, 2015. |
| Results | to consider and approve, inter alia Unaudited Financial Results for the second quarter and half year September 30, 2015. |
| Results | To consider and approve inter alia, Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2015. |
| Dividend | To consider and approve inter alia declaration of interim dividend for financial year 2015-16. |
| Results | inter-alia to: ( 1). Consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2016 and ( 2). Consider and approve Financial Statements for the year ended March 31, 2016. |
| Results | To consider and approve inter alia, Unaudited Financial Results of the Company for the first quarter ended June 30, 2016. |
| Results/Dividend | To consider inter alia : 1. Approving and taking on record Unaudited (Consolidated & Standalone) Financial Results of the Company for the second quarter and half year ended September 30, 2016. 2. Declaration of interim dividend for financial year 2016-17. |
| Results | To consider inter alia approving and taking on record Unaudited (Consolidated & Standalone) Financial Results of the Company for the third quarter ended December 31, 2016. |
| Dividend | to consider and approve inter-alia payment of second interim dividend for financial year 2016-17. |
| Results | inter-alia to: (1). Consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2017 and (2). Consider and approve Financial Statements for the year ended March 31, 2017. |
| Results | To consider and approve inter-alia, Unaudited consolidated and standalone Financial Results of the Company for the first quarter ended June 30, 2017. |
| Results | To consider and approve inter-alia, Unaudited consolidated and standalone Financial Results of the Company for the second quarter and half year ended September 30, 2017. |
| Results | To consider and approve inter-alia, Unaudited consolidated and standalone Financial Results of the Company for the third quarter ended December 31, 2017. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and dividend |
| Buyback | To consider buyback for equity shares.This is with reference to our letter dated 23rd October 2020, informing you about the Board Meeting of the Company scheduled to be held on Tuesday, 3rd November, 2020 ("Board Meeting"), to consider, inter alia the unaudited consolidated and financial results for the quarter and half year ended 30th September 2020 and interim dividend.Pursuant to Regulation 29(1)(b) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider a proposal for buy-back of the Equity Shares of the Company including matters related /incidental thereto ("Buyback") and any other matter as the Board of Directors of the Company may decide during the course of the meeting.You are requested to please take a note of the same. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results | To consider and approve the unaudited consolidated and standalone financial results for the period ended Jun 30, 2021 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2021 and dividend |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Ajanta Pharma Limited has informed the Exchange about Board Meeting to be held on 28-Jul-2022 to consider financial statements for the period ended June 2022 |
| Dividend | This is with reference to our letter dated 21st October 2022, informing you about the Board meeting scheduled on Thursday, 3rd November 2022 to inter-alia consider and take on record the unaudited financial results for the second quarter and half year ended 30th September 2022.Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for:a. declaration of interim dividend, if any, for the financial year ending 31st March 2023; andb. fixation of Monday, 14th November, 2022 as the Record Date for the payment of interim dividend, if declared.You are requested to please take a note of the same and disseminate to all concerned. |
| Financial results | Ajanta Pharma Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Dividend | To consider dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Dividend | To consider dividend |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2024 and other business matters |
| Buyback | To consider buyback for equity shares |
| Dividend | To consider dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Ajanta Pharma Limited
Voting Results of Ajanta Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 18-JUL-2024 | AGM | 1 - To receive, consider and adopt:na) the Audited Standalone Financial Statements of the Company for the Financial Year ended March 2024 together with the Reports of the Board of Directors and the Auditors thereon; andnb) the Audited Consolidated Financial Statements of the Company for the Financial year ended 31 March 2024 together with the Report of the Auditors thereon. |
| 18-JUL-2024 | AGM | 8 - RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, remuneration of ? 6.50 lakhs plus GST and reimbursement of actual travel and out of pocket expenses, fixed by the Board for M/s. RA & Co., Cost Accountants, (Firm Registration No. 000242), Cost Auditors to conduct the audit of the cost records for the financial year ending 31 March 2025, be and is hereby ratified |
| 18-JUL-2024 | AGM | 7 - RESOLVED THAT pursuant to the provisions of Section 149, 152 read with Schedule IV of the Companies Act 2013 (the Act), Regulation 17 (1C) of SEBI (LODR) Regulations, 2015, Ms. Simi Thapar (DIN: 10470498) be and is hereby appointed as an Independent Director of the Company for a term of 5 (five) years from 2nd May, 2024, not liable to retire by rotation |
| 18-JUL-2024 | AGM | 6 - RESOLVED THAT pursuant to the provisions of Section 149, 152 read with Schedule IV of the Companies Act 2013 (the Act), Regulation 17 (1C) of SEBI (LODR) Regulations, 2015, Mr. RajeshnDalal (DIN: 03504969) be and is hereby appointed as an Independent Director of the Company for a term of 5 (five) years from 2nd May, 2024, not liable to retire by rotation |
| 18-JUL-2024 | AGM | 5 - RESOLVED THAT pursuant to the provisions of Section 149, 152 read with Schedule IV of the Companies Act 2013 (the Act), Regulation 17 (1C) of SEBI (LODR) Regulations, 2015, Ms. Medha Joshi (DIN: 00328174) be and is hereby appointed as an Independent Director of the Company for a term of 5 (five) years from 2nd May, 2024, not liable to retire by rotation |
| 18-JUL-2024 | AGM | 4 - RESOLVED THAT pursuant to the provisions of Section 149, 152 read with Schedule IV of the Companies Act 2013 (the Act), Regulation 17 (1C) of SEBI (LODR) Regulations, 2015, Mr. DavidnRasquinha (DIN: 01172654) be and is hereby appointed as an Independent Director of the Company for a term of 5 (five) years from 2nd May, 2024, not liable to retire by rotation |
| 18-JUL-2024 | AGM | 3 - To appoint a Director in place of Mr. Mannalal B. Agrawal (DIN: 00073828), who retires by rotation and being eligible, offers himself for re-appointment |
| 18-JUL-2024 | AGM | 2 - RESOLVED THAT the first interim dividend of ? 25 per equity share and second interim dividend of ? 26 per equity share approved by the Board of Directors of the Company and already paid, be and are hereby confirmed/ratified |
| 18-JUL-2023 | AGM | Adoption of financial statements for the year ended 31st March 2023 |
| 18-JUL-2023 | AGM | Ratifying remuneration of Cost Auditors, M/s. Sevekari, Khare & Associates for financial year 2023 - 2024 |
| 18-JUL-2023 | AGM | Approve amendment in Object Clause of the Memorandum of Association of the Company. |
| 18-JUL-2023 | AGM | Approve payment of commission to Non-Executive & Independent Directors for a period of 5 years. |
| 18-JUL-2023 | AGM | Re-appointment of Mr. Madhusudan B. Agrawal, retiring by rotation |
| 18-JUL-2023 | AGM | Confirm interim dividend as final dividend |
| 09-MAR-2023 | Postal Ballot | RE-APPOINTMENT OF MR. YOGESH M. AGRAWAL AS MANAGING DIRECTOR |
| 09-MAR-2023 | Postal Ballot | RE-APPOINTMENT OF MR. RAJESH M. AGRAWAL AS JOINT MANAGING DIRECTOR |
| 04-AUG-2022 | AGM | Adoption of financial statements for the year ended 31st March 2022 |
| 04-AUG-2022 | AGM | Re-appointment of M/s. BSR & Co. LLP, Statutory Auditors, for a second term of five consecutive years |
| 04-AUG-2022 | AGM | Re-appointment of Mr. Mannalal B. Agrawal, retiring by rotation |
| 04-AUG-2022 | AGM | Confirm interim dividend as final dividend |
FAQs on Ajanta Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.